This site uses cookies to ensure the best viewing experience for our readers.
Teva Up on NYSE Following Morgan Stanley Stock Recommendation Upgrade

Brief

Teva Up on NYSE Following Morgan Stanley Stock Recommendation Upgrade

Morgan Stanley increased its price target for the generic drugmaker from $20 to $27

CTech | 16:13  05.11.2018
Teva Pharmaceutical Industries Ltd. is up as much as 1.81% on NYSE in pre-market trading following an upgrade from Morgan Stanley. The financial firm and bank upgraded Teva from "equal-weight" to "overweight" and upped its price target from $20 to $27. Teva was $22.57 on Friday market close.

The drugmaker published its third quarter results for 2018 on Thursday, reporting a decrease in revenue both year-over-year and compared to the second quarter of 2018. The company raised its non-GAAP earnings per share guidance for 2018 from $2.55-$2.80 to $2.80-$2.95 and its annual free cash flow guidance from $3.2-$3.4 billion to $3.6-$3.8 billion.

Teva Teva's headquarters, Israel. Photo: Bloomberg Teva

share on facebook share on twitter share on linkedin share on whatsapp share on mail

TAGS